Abstract
International guidelines made RAS (KRAS and NRAS) status a prerequisite for the use of anti-EGFR agents for metastatic colorectal cancer (CRC) patients. Daily, new data emerges on the theranostic and prognostic role of molecular biomarkers; this is a strong incentive for a validated, sensitive, and broadly available molecular screening test. Next-generation sequencing (NGS) has begun to supplant other technologies for genomic profiling. We report here our 2 years of clinical practice using NGS results to guide therapeutic decisions. The Ion Torrent AmpliSeq colon/lung cancer panel, which allows mutation detection in 22 cancer-related genes, was prospectively used in clinical practice (BELAC ISO 15189 accredited method). The DNA of 741 formalin-fixed paraffin-embedded CRC tissues, including primary tumors and metastasis, was obtained from 14 different Belgian institutions and subjected to targeted NGS. Of the tumors tested, 98% (727) were successfully sequenced and 89% (650) harbored at least one mutation. KRAS, BRAF and NRAS mutations were found in 335 (46%), 78 (11%) and 32 (4%) samples, respectively. These mutation frequencies were consistent with those reported in public databases. Moreover, mutations and amplifications in p...Continue Reading
References
May 16, 2012·American Journal of Clinical Pathology·Chanjuan Shi, Kay Washington
Jun 23, 2012·Molecular Cancer Therapeutics·Rodrigo DienstmannJosep Tabernero
Jul 20, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Jan 31, 2013·Genes, Chromosomes & Cancer·Katja TuononenSakari Knuutila
Mar 15, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J FerlayF Bray
Apr 25, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J H van KriekenUNKNOWN Quality Assurance for Molecular Pathology group
Aug 8, 2013·PloS One·Clare M McCourtManuel Salto-Tellez
Nov 16, 2013·PloS One·Aldo ScarpaNicola Normanno
May 20, 2014·Histopathology·Marie Le MercierIsabelle Salmon
Jul 6, 2014·Journal of Clinical Pathology·Newton A C S WongShaun V Walsh
Sep 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN ESMO Guidelines Working Group
Dec 3, 2014·The Journal of Molecular Diagnostics : JMD·Marlous HoogstraatMarco J Koudijs
Mar 25, 2015·Cancer Science·Hiroya TaniguchiUNKNOWN Japanese Society of Medical Oncology
Sep 15, 2015·PloS One·Nicky D'HaeneIsabelle Salmon
Oct 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carmen J AllegraRichard L Schilsky
Nov 11, 2015·Cancer Biology & Therapy·Wafik S El-DeirySandeep Reddy
Nov 18, 2015·Virchows Archiv : an International Journal of Pathology·J Han J M Van KriekenAndreas Jung
Jan 23, 2016·Journal of Clinical Pathology·Umberto MalapelleGiancarlo Troncone
Feb 6, 2016·Advances in Anatomic Pathology·Raju K PillaiScott D Patterson
Feb 27, 2016·Genes, Chromosomes & Cancer·Moritz JesinghausAlbrecht Stenzinger
Citations
Aug 21, 2019·Cancers·Javier SimarroSarai Palanca
Jun 21, 2020·Diagnostics·Emese Sarolta BádonGábor Méhes
Jun 7, 2019·Cancers·Nicky D'HaeneIsabelle Salmon
Dec 14, 2018·Oncology Letters·Taicheng ZhouShuang Chen
Jan 30, 2019·Cancers·Carlo CapalboGiuseppe Giannini
Nov 28, 2018·International Journal of Molecular Sciences·Chiara MolinariPaola Ulivi
Aug 30, 2020·Biomedicines·Marco VacanteAntonio Biondi
May 16, 2019·Der Pathologe·J LeichsenringA Stenzinger
Jul 11, 2019·Diagnostic Cytopathology·Kelsey E McHughJordan P Reynolds
Oct 1, 2020·Computational and Structural Biotechnology Journal·Zodwa DlaminiRahaba Marima
Aug 19, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Youngwoo LeeYeul Hong Kim
Aug 24, 2019·Translational Oncology·Dohee KwonKyoung-Mee Kim
Apr 16, 2021·BMC Medical Genomics·Mustafa ÖzdoğanGeorge Nasioulas